189:●OpRegen®, a single-injection retinal pigment epithelium cell replacement therapy currently in a Phase 1/2a multicenter clinical trial for the treatment of advanced dry age-related macular degeneration (“AMD”) with geographic atrophy (GA). There currently are no therapies approved by the U.S. Food and Drug Administration (“FDA”) for dry AMD, which accounts for approximately 85-90% of all AMD cases and is the leading cause of blindness in people over the age of 60. Interim data from 9 months of follow-up post-injection for Cohort 4 was reported in September 2021, highlights improved baseline visions and smaller areas of GA compared to prior cohorts. Overall, OpRegen has proven to be well tolerated to date with no serious adverse events not previously reported. Overall, 8/12 of Cohort 4 patients' treated eyes showed above baseline visual acuity at the last assessment, while 9/12 of the patients' untreated eyes were below baseline visual acuity at the same assessment interval. In May 2022, data was presented at the 2022 Association for Research in Vision and Ophthalmology Annual Meeting: OpRegen Phase 1/2a clinical results support the potential for OpRegen to slow, stop or reverse disease progression in geographic atrophy secondary to age-related macular degeneration. 12-month primary endpoint data suggested OpRegen was well tolerated with an acceptable safety profile. Preliminary evidence of visual function and outer retinal structure improvements observed in five Cohort 4 patients with GA and impaired vision. In December 2021, Lineage announced that the company entered a $ 670 million exclusive worldwide collaboration Genentech, a member of the Roche Group, for the development and commercialization of OpRegen.
183:, the acquisition of Asterias Biotherapeutics and conducting management changes which altogether focused the company mission on developing novel therapies based on directed differentiation and transplant of specific cell types. Since then, Lineage’s focus has been to develop therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. Specifically, Lineage is testing therapies to treat dry age-related macular degeneration, spinal cord injuries, non-small cell lung cancer, auditory neuropathy, and vision loss. Lineage’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. From this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are transplanted into a patient either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. In October 2022, Lineage announced the establishment of a new R&D facility in Carlsbad, California, as well as an expansion to the company’s existing GMP manufacturing facility in Israel. The new facility in Carlsbad will broaden Lineage’s R&D capabilities in the U.S. and support the development of current and future allogeneic cell transplant programs, while the expansion in Israel will increase the company’s infrastructure, including development and optimization of larger-scale clinical manufacturing processes.
38:
150:
differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer.
170:
clinical development for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; and (v) PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage.
178:
Lineage is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. The company changed its name from BioTime Inc. to
Lineage Cell Therapeutics less than one year following its appointment of a new CEO, Brian Culley, in August 2018 and completing a series of
169:
Group; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; (iii) VAC2, an allogeneic dendritic cell therapy produced from
Lineage's VAC technology platform for immuno-oncology and infectious disease, currently in Phase 1
149:
company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform
Lineage develops and manufactures specialized, terminally
894:
470:
209:â—ŹPNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage. Process development and preclinical activities in support of ongoing and planned preclinical testing for the program are ongoing.
1006:
1177:
1079:
672:
206:â—ŹANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy. Process development and preclinical activities in support of planned preclinical testing for the program are ongoing.
566:"A Cancer Research UK Phase I Trial of AST-VAC2 (Allogeneic Dendritic Cell Vaccine) Administered Weekly Via Intradermal Injection in Patients With Non-small Cell Lung Cancer (NSCLC) in the Advanced and Adjuvant Settings"
1201:
192:●OPC1, an oligodendrocyte progenitor cell therapy currently in a Phase 1/2a multicenter clinical trial for acute spinal cord injuries (“SCI”). This clinical trial has been partially funded by the
871:"RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration"
794:
199:â—ŹVAC2, a cancer immunotherapy of antigen-presenting dendritic cells currently in a Phase 1 clinical trial in non-small cell lung cancer. This clinical trial is being funded and conducted by
1128:
1178:"AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute Respiratory Distress Syndrome"
895:"Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders"
471:"Lineage Establishes Exclusive Worldwide Collaboration With Genentech for the Development and Commercialization of OpRegen® RPE Cell Therapy for the Treatment of Ocular Disorders"
1031:
624:
73:
1104:
1055:
1007:"Lineage Cell Therapeutics and Cancer Research UK Announce Encouraging Preliminary Phase 1 Study Results With VAC2 for the Treatment of Non-small Cell Lung Cancer"
1367:
1153:
1362:
944:
721:
1382:
968:
1080:"Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness"
673:"Lineage Announces a Fifth Cell Therapy Program: Allogeneic Photoreceptor Transplants for the Treatment of Diseases Which May Lead to Blindness"
499:"Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration – Full Text View – ClinicalTrials.gov"
193:
1392:
1387:
746:
157:(“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy for the treatment of dry
945:"A Phase I/IIa Dose Escalation Safety Study of AST-OPC1 in Patients with Cervical Sensorimotor Complete Spinal Cord Injury"
1243:
158:
770:
870:
1032:"Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss"
625:"Lineage Announces Pipeline Expansion to Include Auditory Neuronal Cell Therapy for Treatment of Hearing Loss"
153:
Lineage’s clinical and preclinical programs are in markets with billion dollar opportunities and include five
1377:
795:"Lineage Establishes New R&D Facility in U.S. and Expands Current GMP Manufacturing Facility in Israel"
1339:
1202:"BioTime Subsidiary OrthoCyte Corporation Announces the Appointment of Francois Binette as Vice President"
527:"A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury"
1105:"Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update"
1056:"Lineage Cell Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update"
586:
547:
69:
17:
186:
Lineage has five allogeneic, or “off-the-shelf,” cell therapy programs in clinical development:
1129:"Lineage Cell Therapeutics Provides Update on OPC1 Cell Therapy Program for Spinal Cord Injury"
1244:"LCTX Company Profile & Executives – Lineage Cell Therapeutics Inc. – Wall Street Journal"
573:
534:
87:
105:
37:
8:
1372:
332:
Stem cell products for research, including clinical grade cell lines produced under cGMP
747:"BioTime announces distribution of Agex Therapeutics shares (NYSE:BTX) | Seeking Alpha"
367:
200:
1284:
962:
822:
446:
180:
1334:
982:
919:
600:
565:
526:
498:
48:
304:
Cell therapy clinical development programs in spinal cord injury and oncology
1356:
697:
648:
146:
83:
62:
56:
1329:
1324:
1154:"Lineage Cell Therapeutics receives grant to fund novel bio-retinal patch"
1344:
346:
Developing bone grafting products for orthopedic diseases and injuries
154:
66:
771:"Lineage Cell Therapeutics Acquires Asterias Biotherapeutics | Mergr"
162:
27:
Clinical-stage biotechnology company developing novel cell therapies
422:
846:
380:
Dipti Amin, MBBS, FFPM, MRCGP, DCPSA, DCH, DRCOG, DGM – Director
161:, which is being developed under a worldwide collaboration with
524:
122:
George A. Samuel III, General
Counsel & Corporate Strategy
166:
722:"BioTime Announces Name Change to Lineage Cell Therapeutics"
1313:
203:, the world’s largest independent cancer research charity.
131:
374:
Alfred D. Kingsley, B.S., J.D. – Chairman of the board
179:
corporate transactions including the distribution of
318:Products to treat age-related macular degeneration
563:
1354:
392:Anula Jayasuriya, M.D., Ph.D., M.B.A. – Director
525:Lineage Cell Therapeutics, Inc. (2020-07-14).
389:Brian M. Culley, B.S., M.S., M.B.A. – Director
194:California Institute for Regenerative Medicine
1320:Business data for Lineage Cell Therapeutics:
847:"Dry Age-related Macular Degeneration – AMDF"
358:(1) Includes shares owned by Lineage and ESI
1368:Biotechnology companies of the United States
1363:Biotechnology companies established in 1990
967:: CS1 maint: numeric names: authors list (
36:
942:
851:American Macular Degeneration Foundation
395:Michael H. Mulroy, B.A., J.D. – Director
14:
1383:Companies based in Alameda, California
1355:
383:Don M. Bailey, B.S., M.B.A. – Director
1279:
1277:
1275:
1273:
1271:
1269:
1267:
1265:
1263:
1238:
1236:
1234:
1232:
1230:
1228:
1226:
1224:
1222:
817:
815:
361:
212:
559:
557:
520:
518:
493:
491:
417:
415:
386:Neal C. Bradsher, C.F.A. – Director
24:
1260:
1219:
812:
398:Angus C. Russel, D.B.A. – Director
25:
1404:
1393:1990 establishments in California
1388:Companies listed on NYSE American
1305:
564:Cancer Research UK (2020-11-10).
554:
515:
488:
412:
377:Deborah Andrews, B.S. – Director
329:ES Cell International Pte. Ltd.
281:Lineage's subsidiaries include:
159:age-related macular degeneration
143:Lineage Cell Therapeutics, Inc.
1194:
1170:
1146:
1121:
1097:
1072:
1048:
1024:
999:
975:
936:
912:
887:
863:
839:
787:
763:
739:
714:
690:
665:
301:Asterias BioTherapeutics, Inc.
276:
31:Lineage Cell Therapeutics, Inc.
641:
617:
593:
463:
439:
13:
1:
949:California's Stem Cell Agency
405:
315:Cell Cure Neurosciences Ltd.
147:clinical-stage biotechnology
7:
10:
1409:
173:
1289:Lineage Cell Therapeutics
987:Lineage Cell Therapeutics
924:Lineage Cell Therapeutics
827:Lineage Cell Therapeutics
702:Lineage Cell Therapeutics
653:Lineage Cell Therapeutics
605:Lineage Cell Therapeutics
451:Lineage Cell Therapeutics
427:Lineage Cell Therapeutics
126:
111:
101:
93:
79:
54:
44:
35:
943:cirm_2.0 (2017-09-26).
581:Cite journal requires
542:Cite journal requires
343:OrthoCyte Corporation
88:regenerative medicine
1378:Cancer organizations
1285:"Board of Directors"
1206:www.businesswire.com
1133:www.businesswire.com
1084:www.businesswire.com
1011:www.businesswire.com
899:www.businesswire.com
799:www.businesswire.com
726:www.businesswire.com
677:www.businesswire.com
475:www.businesswire.com
106:Carlsbad, California
32:
503:clinicaltrials.gov
368:board of directors
362:Board of directors
293:Lineage Ownership
290:Field of Business
213:Leadership history
201:Cancer Research UK
165:, a member of the
30:
356:
355:
274:
273:
181:AgeX Therapeutics
140:
139:
117:Brian Culley, CEO
16:(Redirected from
1400:
1317:
1316:
1314:Official website
1299:
1298:
1296:
1295:
1281:
1258:
1257:
1255:
1254:
1240:
1217:
1216:
1214:
1213:
1198:
1192:
1191:
1189:
1188:
1174:
1168:
1167:
1165:
1164:
1150:
1144:
1143:
1141:
1140:
1125:
1119:
1118:
1116:
1115:
1101:
1095:
1094:
1092:
1091:
1076:
1070:
1069:
1067:
1066:
1052:
1046:
1045:
1043:
1042:
1028:
1022:
1021:
1019:
1018:
1003:
997:
996:
994:
993:
979:
973:
972:
966:
958:
956:
955:
940:
934:
933:
931:
930:
916:
910:
909:
907:
906:
891:
885:
884:
882:
881:
867:
861:
860:
858:
857:
843:
837:
836:
834:
833:
819:
810:
809:
807:
806:
791:
785:
784:
782:
781:
767:
761:
760:
758:
757:
751:seekingalpha.com
743:
737:
736:
734:
733:
718:
712:
711:
709:
708:
694:
688:
687:
685:
684:
669:
663:
662:
660:
659:
645:
639:
638:
636:
635:
621:
615:
614:
612:
611:
597:
591:
590:
584:
579:
577:
569:
561:
552:
551:
545:
540:
538:
530:
522:
513:
512:
510:
509:
495:
486:
485:
483:
482:
467:
461:
460:
458:
457:
443:
437:
436:
434:
433:
419:
284:
283:
242:Mike West, Ph.D.
231:Mike West, Ph.D.
217:
216:
136:
133:
40:
33:
29:
21:
1408:
1407:
1403:
1402:
1401:
1399:
1398:
1397:
1353:
1352:
1349:
1312:
1311:
1308:
1303:
1302:
1293:
1291:
1283:
1282:
1261:
1252:
1250:
1242:
1241:
1220:
1211:
1209:
1200:
1199:
1195:
1186:
1184:
1176:
1175:
1171:
1162:
1160:
1152:
1151:
1147:
1138:
1136:
1127:
1126:
1122:
1113:
1111:
1103:
1102:
1098:
1089:
1087:
1078:
1077:
1073:
1064:
1062:
1054:
1053:
1049:
1040:
1038:
1030:
1029:
1025:
1016:
1014:
1005:
1004:
1000:
991:
989:
981:
980:
976:
960:
959:
953:
951:
941:
937:
928:
926:
918:
917:
913:
904:
902:
893:
892:
888:
879:
877:
869:
868:
864:
855:
853:
845:
844:
840:
831:
829:
821:
820:
813:
804:
802:
793:
792:
788:
779:
777:
769:
768:
764:
755:
753:
745:
744:
740:
731:
729:
720:
719:
715:
706:
704:
696:
695:
691:
682:
680:
671:
670:
666:
657:
655:
647:
646:
642:
633:
631:
623:
622:
618:
609:
607:
599:
598:
594:
582:
580:
571:
570:
562:
555:
543:
541:
532:
531:
523:
516:
507:
505:
497:
496:
489:
480:
478:
469:
468:
464:
455:
453:
445:
444:
440:
431:
429:
421:
420:
413:
408:
402:
364:
279:
215:
176:
130:
120:Jill Howe, CFO
118:
114:
59:
28:
23:
22:
15:
12:
11:
5:
1406:
1396:
1395:
1390:
1385:
1380:
1375:
1370:
1365:
1351:
1350:
1348:
1347:
1342:
1337:
1332:
1327:
1321:
1318:
1307:
1306:External links
1304:
1301:
1300:
1259:
1218:
1193:
1169:
1158:www.healio.com
1145:
1120:
1096:
1071:
1047:
1023:
998:
974:
935:
911:
886:
862:
838:
811:
786:
762:
738:
713:
689:
664:
640:
616:
592:
583:|journal=
553:
544:|journal=
514:
487:
462:
447:"Cell Therapy"
438:
410:
409:
407:
404:
400:
399:
396:
393:
390:
387:
384:
381:
378:
375:
363:
360:
354:
353:
350:
347:
344:
340:
339:
336:
333:
330:
326:
325:
322:
319:
316:
312:
311:
308:
305:
302:
298:
297:
294:
291:
288:
278:
275:
272:
271:
268:
265:
261:
260:
257:
254:
250:
249:
246:
243:
239:
238:
235:
232:
228:
227:
224:
221:
214:
211:
175:
172:
138:
137:
128:
124:
123:
115:
112:
109:
108:
103:
99:
98:
95:
91:
90:
81:
77:
76:
60:
55:
52:
51:
46:
42:
41:
26:
9:
6:
4:
3:
2:
1405:
1394:
1391:
1389:
1386:
1384:
1381:
1379:
1376:
1374:
1371:
1369:
1366:
1364:
1361:
1360:
1358:
1346:
1343:
1341:
1338:
1336:
1333:
1331:
1328:
1326:
1323:
1322:
1319:
1315:
1310:
1309:
1290:
1286:
1280:
1278:
1276:
1274:
1272:
1270:
1268:
1266:
1264:
1249:
1245:
1239:
1237:
1235:
1233:
1231:
1229:
1227:
1225:
1223:
1207:
1203:
1197:
1183:
1179:
1173:
1159:
1155:
1149:
1134:
1130:
1124:
1110:
1106:
1100:
1085:
1081:
1075:
1061:
1057:
1051:
1037:
1033:
1027:
1012:
1008:
1002:
988:
984:
978:
970:
964:
950:
946:
939:
925:
921:
915:
900:
896:
890:
876:
875:www.yahoo.com
872:
866:
852:
848:
842:
828:
824:
818:
816:
800:
796:
790:
776:
772:
766:
752:
748:
742:
727:
723:
717:
703:
699:
693:
678:
674:
668:
654:
650:
644:
630:
626:
620:
606:
602:
596:
588:
575:
567:
560:
558:
549:
536:
528:
521:
519:
504:
500:
494:
492:
476:
472:
466:
452:
448:
442:
428:
424:
418:
416:
411:
403:
397:
394:
391:
388:
385:
382:
379:
376:
373:
372:
371:
369:
359:
351:
348:
345:
342:
341:
337:
334:
331:
328:
327:
323:
320:
317:
314:
313:
309:
306:
303:
300:
299:
295:
292:
289:
286:
285:
282:
270:2018-Present
269:
266:
263:
262:
258:
255:
252:
251:
247:
244:
241:
240:
236:
233:
230:
229:
226:Years Active
225:
222:
219:
218:
210:
207:
204:
202:
197:
195:
190:
187:
184:
182:
171:
168:
164:
160:
156:
151:
148:
144:
135:
129:
125:
121:
116:
110:
107:
104:
100:
96:
92:
89:
85:
84:Biotechnology
82:
78:
75:
71:
68:
64:
61:
58:
53:
50:
47:
43:
39:
34:
19:
1292:. Retrieved
1288:
1251:. Retrieved
1247:
1210:. Retrieved
1208:. 2012-11-01
1205:
1196:
1185:. Retrieved
1181:
1172:
1161:. Retrieved
1157:
1148:
1137:. Retrieved
1135:. 2020-06-25
1132:
1123:
1112:. Retrieved
1108:
1099:
1088:. Retrieved
1086:. 2022-04-25
1083:
1074:
1063:. Retrieved
1059:
1050:
1039:. Retrieved
1035:
1026:
1015:. Retrieved
1013:. 2020-10-13
1010:
1001:
990:. Retrieved
986:
977:
952:. Retrieved
948:
938:
927:. Retrieved
923:
914:
903:. Retrieved
901:. 2021-12-20
898:
889:
878:. Retrieved
874:
865:
854:. Retrieved
850:
841:
830:. Retrieved
826:
803:. Retrieved
801:. 2022-10-03
798:
789:
778:. Retrieved
774:
765:
754:. Retrieved
750:
741:
730:. Retrieved
728:. 2019-07-31
725:
716:
705:. Retrieved
701:
692:
681:. Retrieved
679:. 2022-04-25
676:
667:
656:. Retrieved
652:
643:
632:. Retrieved
628:
619:
608:. Retrieved
604:
595:
574:cite journal
535:cite journal
506:. Retrieved
502:
479:. Retrieved
477:. 2021-12-20
474:
465:
454:. Retrieved
450:
441:
430:. Retrieved
426:
401:
365:
357:
280:
277:Subsidiaries
264:Brian Culley
208:
205:
198:
191:
188:
185:
177:
152:
142:
141:
119:
102:Headquarters
45:Company type
1340:SEC filings
1248:www.wsj.com
287:Subsidiary
253:Adi Mohanty
132:lineagecell
1373:Stem cells
1357:Categories
1294:2020-12-22
1253:2020-12-22
1212:2020-12-22
1187:2020-12-22
1163:2020-12-22
1139:2020-12-22
1114:2022-11-16
1090:2022-11-16
1065:2022-11-16
1041:2022-11-16
1017:2020-12-16
992:2020-12-16
954:2020-12-16
929:2020-12-16
905:2022-11-16
880:2022-11-16
856:2020-12-16
832:2020-12-16
823:"OpRegen®"
805:2022-11-16
780:2021-09-22
756:2021-09-22
732:2021-09-22
707:2022-11-16
698:"Pipeline"
683:2022-11-16
658:2022-11-16
649:"Pipeline"
634:2022-11-16
610:2022-11-16
508:2020-12-14
481:2022-11-16
456:2020-12-14
432:2020-12-14
406:References
370:includes:
366:Lineage’s
338:Singapore
259:2015-2018
248:2015-2018
237:2007-2015
155:allogeneic
113:Key people
1325:Bloomberg
775:mergr.com
423:"Company"
163:Genentech
57:Traded as
1182:BioSpace
1109:BioSpace
1060:BioSpace
1036:BioSpace
963:cite web
629:BioSpace
321:99% (1)
296:Country
196:(CIRM).
80:Industry
1335:Reuters
324:Israel
174:History
127:Website
94:Founded
72::
65::
18:BioTime
1345:Yahoo!
1330:Google
983:"VAC2"
920:"OPC1"
601:"VAC2"
349:99.8%
256:Co-CEO
245:Co-CEO
49:Public
335:100%
307:100%
223:Title
167:Roche
145:is a
969:link
587:help
548:help
352:USA
310:USA
220:Name
134:.com
97:1990
74:LCTX
70:TASE
67:LCTX
63:AMEX
267:CEO
234:CEO
1359::
1287:.
1262:^
1246:.
1221:^
1204:.
1180:.
1156:.
1131:.
1107:.
1082:.
1058:.
1034:.
1009:.
985:.
965:}}
961:{{
947:.
922:.
897:.
873:.
849:.
825:.
814:^
797:.
773:.
749:.
724:.
700:.
675:.
651:.
627:.
603:.
578::
576:}}
572:{{
556:^
539::
537:}}
533:{{
517:^
501:.
490:^
473:.
449:.
425:.
414:^
86:,
1297:.
1256:.
1215:.
1190:.
1166:.
1142:.
1117:.
1093:.
1068:.
1044:.
1020:.
995:.
971:)
957:.
932:.
908:.
883:.
859:.
835:.
808:.
783:.
759:.
735:.
710:.
686:.
661:.
637:.
613:.
589:)
585:(
568:.
550:)
546:(
529:.
511:.
484:.
459:.
435:.
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
